Provectus Biopharmaceuticals Files 8-K

TL;DR

Provectus Biopharma dropped an 8-K on 12/5 - check it for deets.

AI Summary

On December 5, 2024, Provectus Biopharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware with its principal office in Knoxville, Tennessee, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing provides an update on the company's activities and financial status, which is important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for other events and financial statements, not indicating any immediate significant risks.

Key Players & Entities

• PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Knoxville, Tennessee (location) — Business address
• December 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — 0,000 shares of common stock, par value $0.001 per share (the "Common Stock") and 1,00
• $1,000,000 — d Investors shall invest in VisiRose: $1,000,000 upon request at the lesser of a post-mo
• $20 million — the lesser of a post-money valuation of $20 million or a twenty-five percent (25%) discount
• $26.67 m — oney valuation is less than or equal to $26.67 million, $1,000,000 within thirty (30)
• $25 million — the lesser of a post-money valuation of $25 million or at the Discount if the Series A Roun
• $33.33 m — oney valuation is less than or equal to $33.33 million, and $1,000,000 within two (2)
• $33.33 million — the lesser of a post-money valuation of $33.33 million or at the Discount if the Series A Roun
• $44.44 million — oney valuation is less than or equal to $44.44 million. On December 5, 2004, pursuant to the
• $2,000,000 — Rose until VisiRose receives a total of $2,000,000 of qualified investment. Item 9.01. F

Filing Documents

• form8-k.htm (8-K) — 48KB
• ex99-1.htm (EX-99.1) — 17KB
• ex99-2.htm (EX-99.2) — 26KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• ex99-2_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-049571.txt ( ) — 279KB
• pvct-20241205.xsd (EX-101.SCH) — 3KB
• pvct-20241205_lab.xml (EX-101.LAB) — 33KB
• pvct-20241205_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 800 S. Gay Street , Suite 1610 , Knoxville , Tennessee 37929 (Address of Principal Executive Offices) (Zip Code) (866) 594-5999 (Registrant's Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: None Title of each class Trading Symbol(s) Name of each exchange on which registered Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On December 5, 2024, the Board of Directors (the "Board") of Provectus Biopharmaceuticals, Inc. (the "Company") approved the formation of a subsidiary of the Company to be incorporated under the laws of the State of Delaware under the name VisiRose, Inc. ("VisiRose") and to pursue the development and commercialization of the Company's pharmaceutical-grade active pharmaceutical ingredient ("API") rose bengal sodium for the treatments of ophthalmology diseases and disorders. The certificate of incorporation of VisiRose was filed with the secretary of state of Delaware on December 5, 2024. A copy of VisiRose's Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the Company's Press Release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to the Company's exclusive license agreement with the University of Miami (the "University") for the development and commercialization of the University's intellectual property related to photodynamic antimicrobial therapy in ophthalmology entered into on March 21, 2024 (the "License Agreement"), the Board approved the transfer of certain assets to VisiRose, such as the License Agreement, and the Company's exclusive master supply agreement for API and investigational drug product, subject to final review and contract finalization by the Board. VisiRose shall have an initial authorized capital stock of 5,000,000 shares, consisting of 4,000,000 shares of common stock, par value $0.001 per share (the "Common Stock") and 1,000,000 shares of preferred stock, par value $0.001 per share. Pursuant to the License Agreement, the Board approved the issuances of 95,000 shares of Class A Common Stock (the "Class A Shares") to the Company and 5,000 Class A Shares to the University. The Board also approved the appointment of the following individuals as the initial directors of VisiRose's board: independent directors of the Company Webster Bailey and Jack Lacey, III, MD, chairman and chief executive officer of the Company Ed Pershing as chairman of VisiRose, and president of the Company Dominic Rodrigues. The Board also approved the following individuals as the initial officers of VisiRose: Dominic Rodrigues as Acting Chief Executive Officer of VisiRose, and Chief Financial Officer of the Company Heather Raines as Acting Chief Financial Officer of VisiRose. On October 31, 2024, the Company entered into a non-binding seed round investment term sheet for VisiRose (the "Seed Round Term Sheet") with non-related party investors (the "Seed Investors"), subject to final review and contract finalization by the Board. The Seed Investors shall invest in VisiRose: $1,000,000 upon request at the lesser of a post-money valuation of $20 million or a twenty-five percent (25%) discount (the "Discount) to the valuation of a potential Series A investment round (the "S

View Full Filing

View this 8-K filing on SEC EDGAR